科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02171 科济药业-B

交易中 07-03 11:21:36

15.660

+0.490

+3.23%

最高15.900	最低15.130	成交量200.25万
今开15.170	昨收15.170	日振幅5.08%
总市值93.18亿	流通市值93.18亿	总股本5.95亿
成交额3,113万	换手率0.34%	流通股本5.95亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02171","market":"HK","secType":"STK","nameCN":"科济药业-B","latestPrice":15.66,"timestamp":1783048890429,"preClose":15.17,"halted":0,"volume":2002500,"delay":0,"changeRate":0.03230059327620305,"floatShares":595000000,"shares":595000000,"eps":-0.177264,"marketStatus":"交易中","change":0.49,"latestTime":"07-03 11:21:36","open":15.17,"high":15.9,"low":15.13,"amount":31128780,"amplitude":0.050758,"askPrice":15.68,"askSize":2000,"bidPrice":15.62,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.182,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1783051200000},"marketStatusCode":2,"adr":0,"listingDate":1623945600000,"exchange":"SEHK","adjPreClose":15.17,"openAndCloseTimeList":[[1783042200000,1783051200000],[1783054800000,1783065600000]],"volumeRatio":0.612194,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02171","defaultTab":"news","newsList":[{"id":"1166793389","title":"异动解读｜科济药业-B盘中上涨5.19%，回购计划与板块联动共振延续反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1166793389","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166793389?lang=zh_cn&edition=full","pubTime":"2026-07-02 15:11","pubTimestamp":1782976287,"startTime":"0","endTime":"0","summary":"7月2日，科济药业-B盘中上涨5.19%，报15.0港元/股，成交额6943.42万港元。此外，当日生物科技板块整体走强，康方生物涨7.78%、科伦博泰生物涨7.7%、三生制药涨7.34%、信达生物涨6.78%，板块联动效应助推个股延续反弹。此前公司全球首款实体瘤CAR-T产品恺力美获批上市后股价连续回调，回购计划叠加板块回暖为短期走势提供修复动能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187413060","title":"异动解读｜科济药业-B盘中上涨6.31%，回购计划叠加板块回暖提振反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1187413060","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187413060?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:14","pubTimestamp":1782699291,"startTime":"0","endTime":"0","summary":"6月29日，科济药业-B盘中上涨6.31%，报13.93港元/股，成交额3484.46万港元。此前该股在全球首款实体瘤CAR-T产品恺力美获批上市后连续四日下跌，累计跌幅超20%，回购计划的推出对市场信心形成一定支撑。当日生物科技板块整体走强，康方生物涨7.86%、三生制药涨6.73%、信达生物涨5.46%，板块联动效应亦助推个股反弹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144638759","title":"港股直击 | 董事会批准股份回购计划，科济药业-B午后走高超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1144638759","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144638759?lang=zh_cn&edition=full","pubTime":"2026-06-26 13:47","pubTimestamp":1782452837,"startTime":"0","endTime":"0","summary":"科济药业-B( $科济药业-B(02171)$ )午后拉升超3%，截至发稿，升2.9%，报12.78港元，成交额9608.51万港元。科济药业午间公布，董事会已批准一项股份购回计划，自2026年6月25日起至下一届股东周年大会结束为止，在公开市场上购回不超过约3012万股，即相当于截至2026年5月31日已发行股份总数的约5%。股份购回所用资金来自非IPO募集资金，其中包括业务发展收入、利息收入及其他补贴。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/c0570689f988238b492caefa22fe8d8d","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/c0570689f988238b492caefa22fe8d8d"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646828339","title":"港股异动 | 科济药业-B(02171)午后涨超3% 拟回购不超过5%的公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2646828339","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646828339?lang=zh_cn&edition=full","pubTime":"2026-06-26 13:35","pubTimestamp":1782452111,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B午后拉升超3%，截至发稿，涨2.9%，报12.78港元，成交额9608.51万港元。消息面上，科济药业午间公布，董事会已批准一项股份购回计划，自2026年6月25日起至下一届股东周年大会结束为止，在公开市场上购回不超过约3012万股，即相当于截至2026年5月31日已发行股份总数的约5%。近期，科济药业宣布自主研发的Claudin18.2自体人源化CAR-T细胞治疗产品恺力美新药上市申请已获国家药监局批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK1161","BK1585","VXUS","BK1574","02171","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197913579","title":"科济药业-B批准回购最多3012万股股份，约占已发行股份5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1197913579","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197913579?lang=zh_cn&edition=full","pubTime":"2026-06-26 12:29","pubTimestamp":1782448155,"startTime":"0","endTime":"0","summary":"科济药业-B董事会已批准一项股份回购计划，授权公司回购最多3012万股股份，这一数量约占其当前已发行股份总数的5%。该计划旨在优化公司资本结构，提升股东价值，并可能根据市场状况及公司资金安排适时在公开市场执行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1585","BK1587","BK1161","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191705032","title":"异动解读｜科济药业-B盘中下跌5.07%，全球首款实体瘤CAR-T获批后连续四日承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1191705032","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191705032?lang=zh_cn&edition=full","pubTime":"2026-06-26 11:43","pubTimestamp":1782445434,"startTime":"0","endTime":"0","summary":"6月26日，科济药业-B盘中下跌5.07%，报11.79港元/股，成交额6314.21万港元。这已是该股自6月22日获批消息公布后连续第四个交易日下跌。消息面上，6月22日科济药业宣布其自研CAR-T产品恺力美获批上市，成为全球首个针对实体瘤的CAR-T疗法，定价99万元/人份，用于治疗晚期胃/食管胃结合部腺癌。此前三个交易日该股累计跌幅已超20%。同行业康方生物跌4.97%、荣昌生物跌3.07%、信达生物跌2.37%，板块整体承压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646823620","title":"港股异动 | 科济药业-B(02171.HK)再跌超10% 全球首款实体瘤CAR-T一针99万 预计今年接受订单仅为200单","url":"https://stock-news.laohu8.com/highlight/detail?id=2646823620","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646823620?lang=zh_cn&edition=full","pubTime":"2026-06-25 10:36","pubTimestamp":1782355017,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1585","02171","BK1587","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169533669","title":"异动解读｜科济药业盘中下跌5.46%，全球首款实体瘤CAR-T获批后股价连续三日承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1169533669","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169533669?lang=zh_cn&edition=full","pubTime":"2026-06-25 09:48","pubTimestamp":1782352083,"startTime":"0","endTime":"0","summary":"6月25日，科济药业盘中下跌5.46%，报12.93港元/股，成交额4041.61万港元。这已是该股连续第三个交易日下跌。消息面上，6月22日科济药业宣布其自研CAR-T产品舒瑞基奥仑赛注射液获批上市，成为全球首个针对实体瘤的CAR-T疗法，定价99万元/人份，用于治疗Claudin18.2阳性、HER2阴性的晚期胃/食管胃结合部腺癌。然而获批消息公布后，股价持续走低，6月23日收跌6.36%，6月24日再跌6.03%。同行业康方生物跌4.51%、信达生物跌2.63%、荣昌生物跌3.41%，板块整体承压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187633040","title":"异动解读｜科济药业盘中下跌6.03%，全球首款实体瘤CAR-T获批后股价持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1187633040","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187633040?lang=zh_cn&edition=full","pubTime":"2026-06-24 10:09","pubTimestamp":1782266977,"startTime":"0","endTime":"0","summary":"6月24日，科济药业盘中下跌6.03%，报14.8港元/股，成交额4240.98万港元。此前一个交易日，该股已收跌6.36%。消息面上，6月22日科济药业宣布其自研CAR-T产品舒瑞基奥仑赛注射液获批上市，成为全球首个针对实体瘤的CAR-T疗法，定价99万元/人份，用于治疗Claudin18.2阳性、HER2阴性的晚期胃/食管胃结合部腺癌。值得注意的是，同行业康方生物、信达生物、百济神州等当日均录得涨幅，科济药业表现明显弱于板块。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161041485","title":"科济药业宣布全球首个实体瘤CAR-T疗法产品Satri-Cel获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1161041485","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161041485?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:21","pubTimestamp":1782127273,"startTime":"0","endTime":"0","summary":"科济药业-B（CARSGEN-B）宣布，其CAR-T细胞疗法产品Satri-Cel已获得批准，成为全球首个用于治疗实体瘤的CAR-T细胞疗法产品。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171","BK1587","BK1161","BK1585","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645400610","title":"科济药业：自研CAR-T细胞治疗产品恺力美获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2645400610","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645400610?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:53","pubTimestamp":1782118380,"startTime":"0","endTime":"0","summary":"6月22日，科济药业（02171）发布公告，国家药品监督管理局批准公司自主研发的Claudin18.2自体人源化CAR-T细胞治疗产品恺力美?（舒瑞基奥仑赛注射液）的新药上市申请。公告指出，恺力美?用于治疗Claudin18.2阳性、人表皮生长因子受体2（HER2）阴性，至少二线治疗失败的晚期胃/食管胃结合部腺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606223778072646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CAR","BK1574","BK4022","BK4230","BK1161","BK1585","BK1587","02171","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166977495","title":"科济药业靶向GPC3 CAR-T疗法获NMPA批准用于晚期胃癌/胃食管结合部癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1166977495","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166977495?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:35","pubTimestamp":1782117334,"startTime":"0","endTime":"0","summary":"中国国家药品监督管理局已批准科济药业旗下的靶向GPC3的自体CAR-T细胞产品Satricabtagene Autoleucel，用于治疗既往接受过至少两种系统治疗的GPC3阳性晚期胃癌/胃食管结合部腺癌患者。此项批准标志着全球范围内首个针对GPC3靶点的CAR-T细胞疗法成功获批上市，为晚期胃癌患者带来了全新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1585","BK1587","02171","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645414460","title":"“百万元一针”抗癌药有望降至万元，科济药业研发通用型CAR-T疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2645414460","media":"上观新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645414460?lang=zh_cn&edition=full","pubTime":"2026-06-22 14:57","pubTimestamp":1782111437,"startTime":"0","endTime":"0","summary":"科济药业创始人、首席执行官李宗海博士介绍，科济药业已将研发重心从自体CAR-T（嵌合抗原受体T细胞）转向通用型CAR-T疗法。自体CAR-T疗法利用人体自身免疫系统开展个体化治疗：先通过白细胞分离，从患者体内提取T细胞；再用CAR（嵌合抗原受体）对其修饰，让T细胞能识别癌细胞上特定抗原；完成基因工程修饰后，将CAR-T制剂回输给这名患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606223777971181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CAR","BK4230","BK1587","BK1161","02171","BK1574","BK1585","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643222786","title":"港股异动 | 科济药业-B(02171)涨超5% CT0596和CT1190B研究结果已于EHA年会上进行壁报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2643222786","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643222786?lang=zh_cn&edition=full","pubTime":"2026-06-15 13:50","pubTimestamp":1781502601,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B(02171)涨超5%，截至发稿，涨4.86%，报15.75港元，成交额8618.49万港元。消息面上，6月15日，科济药业-B发布公告，CT0596(一种靶向BCMA的通用型CAR-T细胞产品)用于治疗复发 ╱ 难治性多发性骨髓瘤(R/R MM)和浆细胞白血病(PCL)的研究结果，及CT1190B(一种靶向CD19/CD20的通用型CAR-T细胞产品)用于治疗复发╱难治性B细胞非霍奇金淋巴瘤(R/R B-NHL)的研究结果，已在2026年欧洲血液学协会(EHA)年会上进行壁报展示。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1587","BK1585","BK4588","BK4585","VXUS","02171","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643223592","title":"科济药业-B(02171)于2026年EHA年会上展示CT0596和CT1190B研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2643223592","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643223592?lang=zh_cn&edition=full","pubTime":"2026-06-15 08:12","pubTimestamp":1781482357,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B 公布，CT0596用于治疗复发 ╱ 难治性多发性骨髓瘤和浆细胞白血病的研究结果，及CT1190B用于治疗复发╱难治性B细胞非霍奇金淋巴瘤的研究结果，已在2026 年欧洲血液学协会年会上进行壁报展示。CT1190B的更新结果已于中欧夏令时间2026年6月13日18:45 – 19:45，在2026 EHA年会上进行壁报展示，标题为“通用型抗CD19/CD20 CAR-T细胞疗法 CT1190B在复发或难治性B细胞非霍奇金淋巴瘤患者中的首次人体研究”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454148.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK1161","BK1574","BK1585","02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198289310","title":"科济药业-B更新2026年5月股份变动月报表，股本增至602,493,998股","url":"https://stock-news.laohu8.com/highlight/detail?id=1198289310","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198289310?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:01","pubTimestamp":1780574517,"startTime":"0","endTime":"0","summary":"2026年6月4日，科濟藥業控股有限公司公告了2026年5月股份变动月报表，报告期为2026年5月1日至2026年5月31日。另于2025年5月22日，公司回购455,000股普通股，目前该等股份尚未注销。2026年5月26日，公司以每股19.84港元的价格配售并发行23,700,000股新股，叠加期权行使及股权激励的影响后，本月实际新增发行股份23,733,250股。截至2026年5月31日，公司已发行股份总数达594,675,998股，加上库藏股份后，共有602,493,998股。该月报由公司的执行董事李宗海于2026年6月4日签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162683138","title":"异动解读｜科济药业-B盘中下跌5.14%，折让配股稀释效应叠加板块走弱持续压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1162683138","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162683138?lang=zh_cn&edition=full","pubTime":"2026-06-02 11:33","pubTimestamp":1780371237,"startTime":"0","endTime":"0","summary":"6月2日，科济药业-B盘中下跌5.14%，报16.41港元/股，成交额3187.27万港元。折价配股带来的稀释效应叠加机构持续减持，短期对市场情绪形成压制。资金用途方面，70%将用于创新药全球临床开发，15%用于研发与生产设备设施，15%用于营运资金。此外，港股生物科技板块整体走弱，三生制药跌7.4%、科伦博泰生物跌3.95%、康方生物跌3.02%、百济神州跌2.22%、信达生物跌2.1%，行业估值承压进一步加剧个股调整。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126274477","title":"异动解读｜科济药业-B盘中下跌5.02%，折让配股稀释效应叠加机构减持持续压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1126274477","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126274477?lang=zh_cn&edition=full","pubTime":"2026-06-01 11:08","pubTimestamp":1780283287,"startTime":"0","endTime":"0","summary":"6月1日，科济药业-B盘中下跌5.02%，报17.23港元/股，成交额5237.98万港元。折价配股带来的稀释效应叠加机构持续减持，短期对市场情绪形成压制。资金用途方面，70%将用于创新药全球临床开发，15%用于研发与生产设备设施，15%用于营运资金。此外，港股生物科技板块整体表现分化，信达生物跌2.64%、百济神州跌2.32%、科伦博泰生物跌3.25%，行业估值承压进一步加剧个股调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640642981","title":"科济药业-B(02171)：舒瑞基奥仑赛注射液研究成果于2026年ASCO年会上进行壁报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2640642981","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640642981?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:25","pubTimestamp":1780273534,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B 发布公告，舒瑞基奥仑赛注射液在晚期胃癌╱胃食管交界处腺癌患者中作为一线治疗后的序贯治疗的长期分析研究结果于美国中部夏令时间2026年5月30日13:30 – 16:30在2026年美国临床肿瘤学会年会上进行壁报展示。发表在2026ASCO年会上的摘要标题为“舒瑞基奥仑赛注射液作为晚期胃癌一线治疗后序贯治疗的长期随访 —— 一项亚组分析”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448248.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","02171","BK1585","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129638005","title":"科济药业-B公布Satri-Cel用于胃癌一线治疗后序贯疗法的长期随访结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1129638005","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129638005?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:16","pubTimestamp":1780273010,"startTime":"0","endTime":"0","summary":"在2026年美国临床肿瘤学会（ASCO）年会上，科济药业-B（CARSGEN-B）公布了其CAR-T细胞疗法Satri-Cel作为胃癌一线治疗后序贯疗法的长期随访研究数据。\n这些长期随访结果进一步评估了Satri-Cel在该治疗模式下的疗效与安全性表现。数据显示，该疗法在特定患者群体中展现出持久的临床获益潜力，为晚期胃癌患者提供了新的治疗选择方向。\n此次数据发布是科济药业-B在实体瘤CAR-T疗法领域持续研发进展的体现。公司致力于探索创新细胞疗法在包括胃癌在内的多种癌症治疗中的应用前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","02171","BK1587","BK1585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.carsgen.com","stockEarnings":[{"period":"1week","weight":0.2214},{"period":"1month","weight":-0.0773},{"period":"3month","weight":-0.1751},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.2878},{"period":"ytd","weight":0.0215}],"compareEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":-0.1146},{"period":"3month","weight":-0.0821},{"period":"6month","weight":-0.1247},{"period":"1year","weight":-0.0482},{"period":"ytd","weight":-0.1005}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"科济药业控股有限公司是一家主要从事探索、研发细胞疗法的投资控股公司。该公司的主营业务是从事开发嵌合抗原受体T细胞（CAR-T）细胞疗法，以满足临床需求，包括但不限于血液恶性肿瘤、实体瘤及自身免疫性疾病。该公司的主要产品包括赛恺泽（泽沃基奥仑赛注射液）、舒瑞基奥仑赛注射液、通用型CAR-T细胞产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.07858},{"month":2,"riseRate":0.6,"avgChangeRate":0.230493},{"month":3,"riseRate":0.2,"avgChangeRate":-0.058535},{"month":4,"riseRate":0.4,"avgChangeRate":-0.02351},{"month":5,"riseRate":0.6,"avgChangeRate":0.035849},{"month":6,"riseRate":0.4,"avgChangeRate":-0.015777},{"month":7,"riseRate":0.5,"avgChangeRate":-0.002145},{"month":8,"riseRate":0.6,"avgChangeRate":0.066197},{"month":9,"riseRate":0.4,"avgChangeRate":0.033481},{"month":10,"riseRate":0.6,"avgChangeRate":0.024843},{"month":11,"riseRate":0.6,"avgChangeRate":0.051023},{"month":12,"riseRate":0.4,"avgChangeRate":-0.058482}],"exchange":"SEHK","name":"科济药业-B","nameEN":"CARSGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科济药业-B,02171,科济药业-B股票,科济药业-B股票老虎,科济药业-B股票老虎国际,科济药业-B行情,科济药业-B股票行情,科济药业-B股价,科济药业-B股市,科济药业-B股票价格,科济药业-B股票交易,科济药业-B股票购买,科济药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}